TFP
TEVA icon

Tilia Fiduciary Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Tilia Fiduciary Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$4K – 534
2022
Q2 		$4K Hold
500
– – ﹤0.01% 460
2022
Q1 		$5K Hold
500
– – ﹤0.01% 467
2021
Q4 		$4K Buy
+500
New +$4.51K ﹤0.01% 508

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Tilia Fiduciary Partners's TEVA Position: Q3 2022 in Review

Tilia Fiduciary Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 500 shares — an estimated $4K sold.

Tilia Fiduciary Partners first reported a position in TEVA in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q1 2022. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Tilia Fiduciary Partners reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 500 Teva Pharmaceuticals shares in Q3 2022, an estimated $4K.
  • Tilia Fiduciary Partners first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Tilia Fiduciary Partners's Teva Pharmaceuticals position peaked at $5K in Q1 2022.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2022, filed 27 Oct 2022.